- Home
- IMAX vs ELVN Comparison
IMAX vs ELVN Comparison
Compare IMAX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMAX | ELVN |
|---|---|---|
| Founded | 1967 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMAX | ELVN |
|---|---|---|
| Price | $35.67 | $46.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $44.50 | $43.40 |
| AVG Volume (30 Days) | 991.7K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | 3.17 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $7.51 | N/A |
| P/E Ratio | $55.48 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $22.50 | $14.79 |
| 52 Week High | $43.16 | $48.53 |
Technical Indicators
Market Signals| Indicator | IMAX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 69.28 |
| Support Level | $33.34 | $17.99 |
| Resistance Level | $37.52 | N/A |
| Average True Range (ATR) | 1.44 | 2.51 |
| MACD | -0.30 | 0.29 |
| Stochastic Oscillator | 18.98 | 84.05 |
Price Performance
Historical ComparisonAbout IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.